Japan Bladder Cancer Market

Japan Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2022187 | Category : Pharmaceuticals | Delivery Format: /

Japan bladder cancer market is estimated to grow modestly at a CAGR of around 10.2% during the forecast period. Due to the well-established healthcare industry and awareness about bladder cancer and its treatment, the opportunities for drugs and devices for bladder cancer exist substantially in Japan. The mortality caused due to cancer in Japan is estimated to around 0.37 million in 2017. According to the Tsugane’s contribution to cancer research, the Population Attributable Fraction (PAF) of tobacco smoking to cancer was 24%, alcohol drinking was 6%, and over-intake of salt was 1.4%. The causes of the other 50% of cancer death were not sufficiently clarified. 

Japan bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most used method in the diagnosis and treatment of bladder cancer.  The cystoscopy uses special tools that may be passed through cystoscope to treat exceedingly small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.

The companies which are contributing to the growth of the Japan bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Sysmex Corp., and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the Japan bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

  1. Japan Bladder Cancer Market Research and Analysis by Cancer Type
  2. Japan Bladder Cancer Market Research and Analysis by Diagnosis
  3. Japan Bladder Cancer Market Research and Analysis by Treatment

The Report Covers

  • Comprehensive research methodology of the Japan bladder cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Japan bladder cancer market.
  • Insights about market determinants which are stimulating the Japan bladder cancer market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis 

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants 

4.1. Motivators

4.2. Restraints

4.3. Opportunities 

5. Market Segmentation

5.1. Japan Bladder Cancer Market by Cancer Type

5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma

5.1.2. Squamous Cell Bladder Cancer

5.1.3. Adenocarcinoma

5.1.4. Others (Sarcomas, Carcinoma in Situ)

5.2. Japan Bladder Cancer Market by Diagnosis

5.2.1. Cystoscopy

5.2.2. Biopsy

5.2.3. Urinalysis

5.2.4. Urine Cytology

5.2.5. Intravenous Pyelogram (IVP)

5.2.6. Others (Biomarkers)

5.3. Japan Bladder Cancer Market by Treatment

5.3.1. Surgery

5.3.2. Chemotherapy

5.3.3. Immunotherapy

5.3.4. Radiation Therapy

5.3.5. Others (Targeted Therapy)

6. Company Profiles

6.1. Astellas Pharma Inc.

6.2. AstraZeneca PLC

6.3. Bayer AG

6.4. Bristol-Myers Squibb Co.

6.5. Eli Lilly and Co.

6.6. F. Hoffmann-La Roche AG

6.7. GlaxoSmithKline Plc

6.8. Johnson & Johnson Services, Inc.

6.9. Merck KGaA

6.10. Pfizer Inc.

6.11. Sysmex Corp.

1. JAPAN BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)

2. JAPAN BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2019-2026 ($ MILLION)

3. JAPAN BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)

1. JAPAN BLADDER CANCER MARKET SHARE BY CANCER TYPE, 2019 VS 2026 (%)

2. JAPAN BLADDER CANCER MARKET SHARE BY DIAGNOSIS, 2019 VS 2026 (%)

3. JAPAN BLADDER CANCER MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)